Logo

Enanta Pharmaceuticals, Inc.

ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify… read more

Healthcare

Biotechnology

13 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$12.60

Price

-3.08%

-$0.40

Market Cap

$366.388m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-107.6%

EBITDA Margin

-123.6%

Net Profit Margin

+114.7%

Free Cash Flow Margin

-107.6%

EBITDA Margin

-123.6%

Net Profit Margin

+114.7%

Free Cash Flow Margin
Revenue

$69.213m

-3.4%

1y CAGR

-8.7%

3y CAGR

-9.3%

5y CAGR
Earnings

-$61.984m

+29.4%

1y CAGR

+10.9%

3y CAGR

-5.3%

5y CAGR
EPS

-$2.74

+30.1%

1y CAGR

+12.1%

3y CAGR

-3.6%

5y CAGR
Book Value

$116.587m

$314.704m

Assets

$198.117m

Liabilities

$186.617m

Debt
Debt to Assets

59.3%

-2.8x

Debt to EBITDA
Free Cash Flow

-$9.609m

+55.0%

1y CAGR

+13.2%

3y CAGR

+4.2%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases